BDC Capital Launches $110M Life Sciences Fund

Why It Matters

The fund plugs a critical early‑stage capital gap in Canada’s life‑sciences ecosystem, where investment has fallen 47% YoY, and could accelerate domestic innovation to compete with the U.S. market.

Key Takeaways

• BDC Capital launches $150M CAD (~$111M USD) life sciences fund.
• Fund targets 10‑15 seed and Series A companies.
• Checks range $1‑3M CAD seed, $5‑8M CAD Series A.
• Focus on therapeutics and medical devices where capital is scarce.
• BDC plans second fund in 4‑5 years.

Pulse Analysis

Canada’s life‑sciences sector has struggled to attract the deep‑pocketed early‑stage capital that fuels biotech breakthroughs in the United States. By committing roughly $111 million USD of "patient capital," BDC Capital aims to bridge the financing chasm that has seen total sector investment dip to about $619 million USD in 2025—a 47% decline from the previous year. The fund’s focus on seed and Series A rounds, where hardware costs and regulatory hurdles make capital scarce, directly addresses the market gap highlighted by industry groups and federal reports.

The strategic appointment of Parimal Nathwani, a veteran of Toronto Innovation Acceleration Partners, signals BDC’s intent to blend venture expertise with its public‑sector mandate. Nathwani’s experience scaling life‑science startups and his network of board positions should help the fund source high‑potential companies and provide the hands‑on support often lacking in early‑stage biotech. By targeting 10‑15 companies with investments ranging from $1‑3 million CAD at seed stage to $5‑8 million CAD at Series A, BDC is positioning itself as a catalyst for Canadian firms to reach milestones that attract later‑stage private and strategic investors.

Long‑term, the initiative could reshape Canada’s innovation landscape. If successful, the fund may encourage ancillary services—such as contract research organizations and specialized legal counsel—to expand domestically, reducing reliance on U.S. ecosystems. BDC’s plan to roll out a second, larger fund within five years suggests confidence that the initial vehicle will generate enough pipeline momentum to justify scaling, potentially elevating Canada’s life‑sciences sector from a peripheral player to a more competitive global contender.

Deal Summary

Canada’s Business Development Bank of Canada (BDC) announced the launch of a new $150‑million CAD (≈$110 million USD) life sciences fund, managed by BDC Capital. The fund will target seed‑ and Series A‑stage biotech and medical‑technology companies, with initial investments of $1‑3 million and $5‑8 million. Parimal Nathwani joins as managing partner, and the capital comes from BDC’s balance sheet.